Table 2 Effects of OT analogues on breast cancer cell proliferation in vitro.
From: The oxytocin receptor signalling system and breast cancer: a critical review
Cell lines | Ligands | Conditions | Effects | Reference |
|---|---|---|---|---|
HMEC, B-TEC | OT, 10−9–10−6 M | 10% FCS or serum free, medium changed every 48 h | Stimulation (proliferation & migration) | [91] |
MCF-7 | OT, 10−11–10−9 M | 2.5% FCS | Stimulation | [59] |
VP, 10−8 M | Inhibition | |||
VP, 10−11–10−9 M | Stimulation | |||
MCF-7 | OT, 10−7 M | 2% FCS in medium with E2 or CS-FCS in phenol red-free medium | Inhibition | [92] |
MCF-7, SK-BR-3 | VP, 10−8 M | 5% CS-FCS | Stimulation | [93]a |
Desmopressin, 10−8 M | Inhibition | |||
MDA-MB-231 | OT, 10−7 M | 10% FCS | Inhibition | [94] |
MDA-MB-231, MCF-7 | OT, 10−7 M | 10% FCS for 5 days | Proliferation inhibition, differentiation stimulation | [40] |
MDA-MB-231 | OT, 10−9 M, 10−8 M, 10−7 M AT, 10−8 M, 5 × 10−8 M | 5% FCS, medium changed every 24 h | Inhibition | |
MCF-7, T47D | OT, 10−7 M, 10−8 M | 5% FCS, medium changed every 24 h | No effects | |
10% FCS, E2, TAM, medium changed every 24 h | Inhibition | |||
MDA-MB-231, MDA-MB-361, MDA-MB-468, MCF-7 | OT, 10−9 M, 10−7 M | 5% FCS | No effects | [88] |
Hs578T | OT, unspecified concentration | Not available | No significant short-term effects | [90] |
MCF7, TS/A (mouse) | LVT, 10−8 M, 10−7 M 10−6 M DOTA-LVT, 10−8 M, 10−7 M 10−6 M | 10% FCS | Inhibition No effects | [100]b |
MDA-MB-231 TS/A (mouse) | OT, 10−8 M, 10−7 M | 10% FCS | Inhibition | [68] |
TS/A (mouse) D-R3230AC (rat) | OT, AT, 10−8 M | 10% FCS | Inhibition | [96] |
CMT-U27 (canine) | OT, Desmopressin, 10−6 M | 10% FBS | Inhibition | [153] |
